Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Examining the potential of Intella's nexiguran ziclumeran (nex-z) and Alnylam's nucresiran in treating Transthyretin (ATTR) Amyloidosis

Ticker(s): NTLA, ALNY

Who's the expert?

Institution: Stanford

Cardiologist and physician Scientist at Amyloid Center at major academic center with a focus on Advanced Heart Failure and Transplant Cardiology.
Currently manages 200 patients with ATTR amyloidosis and has published numerous papers on this topic.
Research focuses on amyloidosis, transplant immunology, mechanical circulatory support, and non-ischemic cardiomyopathies.

Interview Goal

This call will discuss the current treatment landscape and the potential of nexiguran ziclumeran (nex-z, NTLA-2001), a CRISPR-based gene editing therapy and Nucresiran (ALN-TTRsc04), an RNAi therapeutic which are being developed for the treatment of ATTR amyloidosis and cardiac disease progression.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.